Prof Ulrike Protzer, working at Helmholtz Munich and the Technical University of Munich (TUM), has received the Bavarian m4 Award for her innovative work on TherVacB, a therapeutic vaccine aimed at curing hepatitis B (HBV). This award, given by the Bavarian Ministry of Economic Affairs, Regional Development, and Energy, highlights significant advancements in medical biotechnology. TherVacB, is at the forefront of efforts to activate antiviral immune responses in patients with chronic hepatitis B, a global health issue that affects millions worldwide.
The m4 Award, which includes a grant of €500,000, supports the further development and clinical testing of TherVacB. This funding is important as it facilitates the transition from preclinical stages to clinical trials, with the ultimate goal of establishing an effective treatment for hepatitis B.
Congratulations 👏
Read more here
VIROFIGHT has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899619.